Melanoma Journal Articles for August 2018
Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation
Eszter Szalai, MD, PhD1,2; Yi Jiang, PhD3; Natasha M. van Poppelen, MD4,5; et alMartine J. Jager, MD, PhD6; Annelies de Klein, PhD5; Emine Kilic, MD, PhD4; Hans E. Grossniklaus, MD1,7
JAMA Ophthalmol. Published online August 2, 2018. doi:10.1001/jamaophthalmol.2018.2986
Dove press
Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition
Authors Sun Z, Zheng L, Liu X, Xing W, Liu X
Received 1 November 2017
Accepted for publication 8 March 2018
Published 6 August 2018 Volume 2018:12 Pages 2413—2421
DOI https://doi.org/10.2147/DDDT.S155798
Clinical Cancer Research
Clinical Trial Brief Report
Rates of ERBB2 Alterations Across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-amplified Acral Melanoma
Lee S Gottesdiener, Shannon O’Connor, Klaus J. Busam, Helen Won, David B. Solit, David M. Hyman and Alexander N Shoushtari
DOI: 10.1158/1078-0432.CCR-18-1397
MEK inhibitors for the treatment of NRAS mutant melanoma
Authors Sarkisian S, Davar D
Received 3 April 2018
Accepted for publication 15 June 2018
Published 20 August 2018 Volume 2018:12 Pages 2553—2565
DOI https://doi.org/10.2147/DDDT.S131721
Ophthalmic Res
Evaluation of Vascular Changes with Optical Coherence Tomography Angiography after Plaque Radiotherapy of Choroidal Melanoma
Cennamo G.b · Breve M.A.b · Velotti N.c · Sparnelli F.b · Iovino C.b · Farella A.d · Liuzzi R.e ·de Crecchio G.b · Cennamo G.a
https://doi.org/10.1159/000490571
Clinical Cancer Research
CCR Translations
Playing the Melanoma Endgame
Jessica L.F. Teh and Andrew E. Aplin
DOI: 10.1158/1078-0432.CCR-18-0989